Cardiovascular diseases represent the major cause of mortality in women and in men.
1,2 However, gender differences in the clinical presentation of cardiovascular diseases have been demonstrated
3 and some therapeutic options may not be equally effective and safe in men and women.
4 Furthermore, gender differences in pharmacokinetics and pharmacodynamics may contribute to a different response to cardiovascular drugs in women when compared with men.
5,6 Accordingly, preventive and therapeutical interventions should be tested in populations that fairly represent the gender distribution. In contrast, under-representation of women in cardiovascular trials has been clearly demonstrated in the past.